December 11, 2006

Low doses of humanized anti-CD20 antibody reported active in non-Hodgkin’s lymphoma

December 10, 2006

Novel protein constructs active against lymphoma in animal models

December 7, 2006

Immunomedics to be awarded U.S. patent for the treatmentof B-cell lymphomas, leukemias and autoimmune diseases

December 6, 2006

Immunomedics announces outcome of 2006 annual meeting of shareholders

December 4, 2006

Immunomedics to present at American Society of Hematology 48th annual meeting

December 4, 2006

Study showed Epratuzumab in combination with Rituximab and chemotherapy is safe, tolerable, and active in aggressive lymphoma

November 21, 2006

Immunomedics to present at Lazard Capital Markets third Annual Life Sciences Conference

November 14, 2006

FDA allows resumption of lupus trials with Epratuzumab

November 13, 2006

Epratuzumab and Rituximab have different modes of action

November 6, 2006

Immunomedics announces first quarter fiscal 2007 results

October 25, 2006

Immunomedics to present at upcoming conferences

August 25, 2006

Immunomedics announces fiscal 2006 results

June 5, 2006

Humanized anti-CD20 antibody appears safe and active in non-Hodgkin’ lymphoma in phase I/II study

- Updated Clinical Results Presented at the 42nd Annual Meeting of American Society of Clinical Oncology (ASCO) -

June 5, 2006

Immunomedics constructs new bispecific antibodies using the dock and lock (DNL) technology

- New DNL Products Bind to Both CD20 and CD22 Antigens -

June 2, 2006

Repeated radioimmunotherapy with 131I-Labetuzumab in colorectal cancer with liver metastases found safe and well-tolerated in initial phase II study

June 1, 2006

Immunomedics to present at 53rd annual meeting of the Society of Nuclear Medicine

May 11, 2006

Immunomedics to present at Rodman & Renshaw 3rd annual Global Healthcare Conference

May 10, 2006

Immunomedics to present at Rodman & Renshaw 3rd annual Global Healthcare Conference

May 10, 2006

Immunomedics announces third quarter fiscal 2006 results

May 10, 2006

Immunomedics and UCB announce worldwide development collaboration and license agreement for Epratuzumab

- Immunomedics will receive initial payments totaling 38 million U.S. dollars -

April 25, 2006

Immunomedics and IBC pharmaceuticals report on a novel protein engineering platform technology

April 24, 2006

Epratuzumab for immunotherapy of lupus results published

February 14, 2006

Immunomedics announces second quarter fiscal 2006 results